论文部分内容阅读
目的:探讨晚期卵巢癌患者外周血与腹腔积液中ERCC1基因表达水平及其临床意义。方法:RT-PCR检测36例晚期卵巢癌患者化疗前外周血与腹腔积液中ERCC1 mRNA表达水平,分析其与腹腔热灌注顺铂治疗疗效的关系。结果:外周血ERCC1 mRNA表达水平显著高于腹腔积液中的表达,两者呈显著正相关(P<0.05)。腹腔积液中ERCC1 mRNA表达水平与热灌注顺铂疗效显著相关,有效组呈低水平表达。外周血ERCC1 mRNA表达与热灌注顺铂疗效无关(P>0.05)。结论:腹腔积液中ER-CC1 mRNA有助于晚期卵巢癌患者腹腔热灌注顺铂疗效预测。
Objective: To investigate the expression of ERCC1 gene in peripheral blood and peritoneal effusion in patients with advanced ovarian cancer and its clinical significance. Methods: The expression of ERCC1 mRNA in peripheral blood and peritoneal effusion of 36 patients with advanced ovarian cancer before chemotherapy was detected by RT-PCR. The relationship between the expression of ERCC1 mRNA and the therapeutic effect of intraperitoneal hyperthermic perfusion of cisplatin was analyzed. Results: The expression of ERCC1 mRNA in peripheral blood was significantly higher than that in ascitic fluid (P <0.05). The expression of ERCC1 mRNA in peritoneal effusion was significantly correlated with the efficacy of hot perfusion of cisplatin, while the effective group showed low level of expression. The expression of ERCC1 mRNA in peripheral blood had no correlation with the effect of hot perfusion of cisplatin (P> 0.05). Conclusion: ER-CC1 mRNA in peritoneal effusion is helpful to predict the efficacy of intraperitoneal hyperthermic cisplatin in patients with advanced ovarian cancer.